Evidence map›Paper›PMID 40755240›Full record

SynthesisAnnals of medicine2025

The impact of antithrombin III supplementation on prognosis during extracorporeal membrane oxygenation: a systematic review and meta-analysis.

Ya-Ting Zeng, Yi-Nan Liu, Zi-Han Chen, Qiang Chen, Kai-Peng Sun

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ya-Ting ZengDepartment of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Yi-Nan LiuDepartment of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Zi-Han ChenDepartment of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Qiang ChenDepartment of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Kai-Peng SunDepartment of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo systematically evaluate the impact of antithrombin III (AT III) supplementation on the prognosis of patients undergoing extracorporeal membrane oxygenation (ECMO). MATERIALS AND

methodsA comprehensive literature search was conducted in PubMed, Web of Science, Embase, and the Cochrane Library for studies assessing the effects of AT III supplementation on ECMO patient outcomes. The risk of bias was assessed using the Cochrane Risk of Bias and The Newcastle-Ottawa Scale.

resultsA total of six studies involving 18,641 ECMO-treated patients were included. The meta-analysis showed that AT III supplementation did not reduce mortality in ECMO patients (RR = 1.17, 95% CI: 0.85-1.60,

conclusionOverall, AT III supplementation does not reduce in-hospital mortality, bleeding, or thrombotic complications in ECMO patients and may even pose risks in certain populations. Therefore, routine AT III supplementation in ECMO patients may be not currently recommended.

Indexed as

Antithrombin IIIExtracorporeal Membrane OxygenationThromboembolismHemorrhageHumansPrognosisThrombosisAntithrombin IIIantithrombin IIIbleeding and thrombotic complicationsECMOmortality

Identifiers

PMID40755240
PMCPMC12322988

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.